Core Viewpoint - BillionToOne, a molecular diagnostics company, is set to raise $200 million through its IPO by offering 3.8 million shares priced between $49 and $55 per share, resulting in a fully diluted market capitalization of $2.7 billion at the midpoint of the proposed price range [1][2] Company Overview - Founded in 2016, BillionToOne focuses on prenatal screening and cancer treatment monitoring, utilizing its Quantitative Counting Templates technology to detect DNA molecules with single-base pair precision [2] - The company plans to list on NASDAQ under the ticker symbol BLLN, with joint bookrunners including JPMorgan, Jefferies, Wells Fargo Securities, and BTIG [2] Product Development - BillionToOne has developed a single-molecule next-generation sequencing (smNGS) platform for prenatal and oncology products, allowing significant insights through simple blood collection [1] - In 2019, the company launched its first prenatal product, UNITY, which is a non-invasive prenatal test for assessing the risk of recessive genetic diseases without requiring paternal samples or invasive procedures [1] - In 2023, BillionToOne introduced two complementary pan-cancer liquid biopsy tests: Northstar Select for guiding treatment choices and Northstar Response, a methylation-based test that quantifies cancer severity at the single-molecule level without tissue biopsy [1] Financial Performance - For the 12 months ending June 30, 2025, BillionToOne reported revenue of $209 million [2]
分子诊断公司BillionToOne(BLLN.US)拟IPO融资2亿美元 每股定价49至55美元